Parkinsons Disease: A Current Perspectives on Parkinsons Disease andKey Bioactive Natural Compounds as Future Potential Drug Candidates / Nabeel Ali, Amna Syeda, Tenzin Topgyal, Naseem Gaur, Asimul Islam
Abstract: Parkinsons disease (PD) is one of the most common types of neurological disorder prevailingworldwide and is rapidly increasing in the elderly population across the globe. The cause ofPD is still unknown, but a number of genetic as well as environmental factors contributing to thepathogenesis of Parkinsons disease have been identified. The hallmark of PD includes dopaminedeficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantianigra in the midbrain. Studying the mutation of associated genes is particularly informative inunderstanding the fundamental molecular and pathogenic changes in PD. Intracellular accumulationof misfolded or degraded protein due to mutated genes leading to the manifestation of mitochondrialdysfunction, oxidative stress followed by multifaceted patho-physiologic symptoms. Other studiesinclude the appearance of both motor and non-motor responses like resting tremor, muscle stiffness,slow movement and anxiety, anaemia, constipation, rapid eye movement sleep behaviour disorder.Many bioactive natural compounds have shown positive pharmacological results in treating a numberof extensive disease models of PD. Despite the availability of end number of potent medicinal plantsaround the world, limited research has been done associated with various neurological disorders, includingPD. The currently available dopamine-based drug treatments have several side-effects, further,not effective enough to combat PD completely. Therefore, various plant-based compounds withmedicinal benefits have grabbed lots of attention of researchers to deal with various life-threateningneurodegenerative disorders like PD. On the basis of literature available till date, here, we have discussedand addressed the molecular basis, current scenario, and the best possible treatment of PD forthe future with minimal or no side-effects using various key bioactive compounds from naturalorigin/medicinal plants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current drug targets - 23(2021), 1, Seite 19 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ali, Nabeel [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (19 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011162031 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011162031 | ||
| 003 | DE-627 | ||
| 005 | 20231128155330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011162031 | ||
| 035 | |a (KFL)prod_DARH_.7390F6CF6840E981EE02398032073549BB9AC5E0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Ali, Nabeel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Parkinsons Disease: A Current Perspectives on Parkinsons Disease andKey Bioactive Natural Compounds as Future Potential Drug Candidates |c Nabeel Ali, Amna Syeda, Tenzin Topgyal, Naseem Gaur, Asimul Islam |
| 264 | 1 | |c 2021 | |
| 300 | |a 1 Online-Ressource (19 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract: Parkinsons disease (PD) is one of the most common types of neurological disorder prevailingworldwide and is rapidly increasing in the elderly population across the globe. The cause ofPD is still unknown, but a number of genetic as well as environmental factors contributing to thepathogenesis of Parkinsons disease have been identified. The hallmark of PD includes dopaminedeficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantianigra in the midbrain. Studying the mutation of associated genes is particularly informative inunderstanding the fundamental molecular and pathogenic changes in PD. Intracellular accumulationof misfolded or degraded protein due to mutated genes leading to the manifestation of mitochondrialdysfunction, oxidative stress followed by multifaceted patho-physiologic symptoms. Other studiesinclude the appearance of both motor and non-motor responses like resting tremor, muscle stiffness,slow movement and anxiety, anaemia, constipation, rapid eye movement sleep behaviour disorder.Many bioactive natural compounds have shown positive pharmacological results in treating a numberof extensive disease models of PD. Despite the availability of end number of potent medicinal plantsaround the world, limited research has been done associated with various neurological disorders, includingPD. The currently available dopamine-based drug treatments have several side-effects, further,not effective enough to combat PD completely. Therefore, various plant-based compounds withmedicinal benefits have grabbed lots of attention of researchers to deal with various life-threateningneurodegenerative disorders like PD. On the basis of literature available till date, here, we have discussedand addressed the molecular basis, current scenario, and the best possible treatment of PD forthe future with minimal or no side-effects using various key bioactive compounds from naturalorigin/medicinal plants | ||
| 700 | 1 | |a Syeda, Amna |e verfasserin |4 aut | |
| 700 | 1 | |a Topgyal, Tenzin |e verfasserin |4 aut | |
| 700 | 1 | |a Gaur, Naseem |e verfasserin |4 aut | |
| 700 | 1 | |a Islam, Asimul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug targets |d Hilversum : Bentham Science Publ., 2000 |g 23(2021), 1, Seite 19 |h Online-Ressource |w (DE-627)KFL000006351 |w (DE-600)2044606-8 |w (DE-576)273880896 |x 1873-5592 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:1 |g pages:19 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-4501&volume=23&issue=1&spage=2 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 1 |h 19 | ||